|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007634,
umls-concept:C0008976,
umls-concept:C0018183,
umls-concept:C0024432,
umls-concept:C0086022,
umls-concept:C0229601,
umls-concept:C0392747,
umls-concept:C0442335,
umls-concept:C0553561,
umls-concept:C1274040,
umls-concept:C1515119,
umls-concept:C1554963,
umls-concept:C1704939,
umls-concept:C1705099,
umls-concept:C1880177,
umls-concept:C2004454
|
|
pubmed:issue |
26
|
|
pubmed:dateCreated |
1997-1-28
|
|
pubmed:abstractText |
To formally test the hypothesis that the granulocyte/macrophage colony-forming unit (GM-CFU) cells can contribute to early hematopoietic reconstitution immediately after transplant, the frequency of genetically modified GM-CFU after retroviral vector transduction was measured by a quantitative in situ polymerase chain reaction (PCR), which is specific for the multidrug resistance-1 (MDR-1) vector, and by a quantitative GM-CFU methylcellulose plating assay. The results of this analysis showed no difference between the transduction frequency in the products of two different transduction protocols: "suspension transduction" and "stromal growth factor transduction." However, when an analysis of the frequency of cells positive for the retroviral MDR-1 vector posttransplantation was carried out, 0 of 10 patients transplanted with cells transduced by the suspension method were positive for the vector MDR-1 posttransplant, whereas 5 of 8 patients transplanted with the cells transduced by the stromal growth factor method were positive for the MDR-1 vector transcription unit by in situ or in solution PCR assay (a difference that is significant at the P = 0.0065 level by the Fisher exact test). These data suggest that only very small subsets of the GM-CFU fraction of myeloid cells, if any, contribute to the repopulation of the hematopoietic tissues that occurs following intensive systemic therapy and transplantation of autologous hematopoietic cells.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-1707696,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-2478216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-2874406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7514051,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7529060,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7552989,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7621234,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7711143,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7756658,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7875237,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7884415,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7901474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-7911343,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-8101754,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-8386712,
http://linkedlifedata.com/resource/pubmed/commentcorrection/8986814-8835224
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
pubmed-author:BachierCC,
pubmed-author:BirdR ERE,
pubmed-author:ChangAA,
pubmed-author:ChengSS,
pubmed-author:ClaxtonDD,
pubmed-author:CoteRR,
pubmed-author:DeisserothA BAB,
pubmed-author:EllersonDD,
pubmed-author:FuS QSQ,
pubmed-author:GilesR ERE,
pubmed-author:HananiaE GEG,
pubmed-author:HesterJJ,
pubmed-author:HolmesFF,
pubmed-author:HolzmayerTT,
pubmed-author:HortobagyiGG,
pubmed-author:KavanaghJJ,
pubmed-author:KorblingMM,
pubmed-author:KudelkaAA,
pubmed-author:OstroveJ MJM,
pubmed-author:PANT HTH,
pubmed-author:RahmanZZ,
pubmed-author:SeongDD,
pubmed-author:TiszaV BVB,
pubmed-author:WR,
pubmed-author:WangTT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
24
|
|
pubmed:volume |
93
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
15346-51
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:8986814-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8986814-Base Sequence,
pubmed-meshheading:8986814-Bone Marrow,
pubmed-meshheading:8986814-Bone Marrow Transplantation,
pubmed-meshheading:8986814-Breast Neoplasms,
pubmed-meshheading:8986814-Colony-Forming Units Assay,
pubmed-meshheading:8986814-Cyclophosphamide,
pubmed-meshheading:8986814-DNA Primers,
pubmed-meshheading:8986814-Etoposide,
pubmed-meshheading:8986814-Female,
pubmed-meshheading:8986814-Gene Therapy,
pubmed-meshheading:8986814-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:8986814-Hematopoietic Stem Cells,
pubmed-meshheading:8986814-Humans,
pubmed-meshheading:8986814-Ovarian Neoplasms,
pubmed-meshheading:8986814-P-Glycoprotein,
pubmed-meshheading:8986814-Polymerase Chain Reaction
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy.
|
|
pubmed:affiliation |
University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
|
